

ANTIMICROBIAL SUSCEPTIBILITY PROFILE (01/01/2022 to 12/31/2022)
MedStar Good Samaritan Hospital

Gram Negative Organisms	Percent Susceptible																			
	Number of Isolates	Amikacin****	Amoxicillin-Clavulanate	Ampicillin	Ampicillin/sulbactam	Aztreonam	Cefazolin (Systemic ^a)	Cefazolin (Urine ^b)	Cefepime	Ceftriaxone	Ciprofloxacin	ESBL (Negative)	Gentamicin****	Levofloxacin	Meropenem	Nitrofurantoin*	Piperacillin/tazobactam	Tetracycline	Tobramycin****	Trimethoprim/Sulfa
Acinetobacter baumannii	46**	68	-	-	52	-	-	39	29	30	-	-	-	-	-	-	-	50	-	
Enterobacter cloacae	85	100	-	0	0	73	-	-	81	67	91	-	97	-	85	39	75	92	97	94
Escherichia coli	297	99	-	43	46	84	34	42	86	83	63	85	89	-	100	94	96	63	87	74
Klebsiella pneumoniae ssp pneumoniae	167	99	-	0	43	64	23	28	67	64	66	66	92	-	95	38	74	56	84	71
Morganella morganii	39	100	-	0	20	95	-	-	100	82	72	-	80	-	97	0	90	47	87	67
Proteus mirabilis	156	99	-	72	76	99	0	62	92	85	71	-	86	-	-	100	97	0	85	78
Pseudomonas aeruginosa	239	100	-	0	-	69	-	-	64	0	72	-	-	-	87	0	76	0	95	0
Serratia marcescens	32	100	-	0	38	100	-	-	89	100	89	-	100	-	100	0	100	0	78	100
Stenotrophomonas maltophilia	71**	-	-	-	-	-	-	-	-	-	-	-	-	88	-	-	-	-	-	100

Gram Positive Organisms	Percent Susceptible																
	Number of Isolates	Ampicillin	Ceftriaxone (meningitis)	Ceftriaxone (non meningitis)	Clindamycin	Daptomycin	Erythromycin	Linezolid	Moxifloxacin	Nitrofurantoin*	Oxacillin	Penicillin (meningitis)	Rifampin	Tetracycline	Trimethoprim/Sulfa	Vancomycin	
Enterococcus faecalis	176	99	-	-	-	99	0	99	-	100	-	-	-	-	20	0	98
Enterococcus faecium	32	53	-	-	-	100	0	94	-	0	-	-	-	-	44	0	38
Methicillin resistant Staphylococcus aureus (MRSA)***	195	0	-	-	48	100	8	100	-	100	0	-	-	97	70	80	100
Methicillin sensitive Staphylococcus aureus (MSSA)	230	0	-	-	75	100	56	100	-	100	100	-	-	99	92	90	100
Staphylococcus coagulase-negative	127	0	-	-	63	99	-	100	-	100	47	-	-	98	100	50	100
Streptococcus pneumoniae	15**	-	93	100	-	-	66	-	100	-	-	86	92	-	-	-	100

Percent Susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient

(-) Drug not tested or drug not indicated

(*) Tested on urine isolate only (**) Due to low incidence, organism incidence consists of totals from MFSMC, MGSH, MHH, and MUMH combined

(***) MRSA rate of the institution was 45% (****) Based on CLSI M100-32nd Ed breakpoints

^a Cefazolin (systemic), MIC ≤ 2 µg/mL susceptible for infections other than uncomplicated UTIs

^b Cefazolin (urine), MIC ≤ 16 µg/mL susceptible